- BDR Pharma has agreed to acquire a controlling stake in Acme Formulation’s oral solid formulations business and its subsidiaries from shareholders led by private equity firm PAG, expanding its CDMO capabilities and manufacturing portfolio.
- The acquisition will provide access to US FDA-approved manufacturing facilities and additional capabilities in thyroid therapies, female sex hormones and general pharmaceutical products, supporting BDR Pharma’s international expansion strategy.
BDR Pharma has announced an agreement to acquire a controlling stake in the oral solid formulations business of Acme Formulation Private Limited and its subsidiaries from existing shareholders led by private equity firm PAG. The transaction is intended to strengthen BDR Pharma’s contract development and manufacturing organization (CDMO) capabilities and expand its pharmaceutical portfolio across international markets, particularly the United States. Financial terms of the acquisition were not disclosed.
The acquisition aligns with BDR Pharma’s growth priorities in oncology, critical care and women’s healthcare. It will add manufacturing capabilities in thyroid therapies, female sex hormones and general pharmaceutical products. The acquired business operates US Food and Drug Administration (FDA)-approved manufacturing facilities, which BDR Pharma plans to combine with its recently acquired portfolio of Abbreviated New Drug Applications (ANDAs) and products targeting the US market.
BDR Pharma intends to use the acquired manufacturing infrastructure and available capacity to gradually commercialize its own product portfolio while expanding its CDMO and contract manufacturing services. Dharmesh Shah, chairman and managing director of BDR Pharma, said the acquisition forms part of the company’s broader growth strategy, with further strategic initiatives expected as it expands internationally.
Following the transaction, PAG and Viral Shah will retain full ownership of Immacule, a sterile injectable contract manufacturing business. Immacule operates two facilities in Nalagarh, Himachal Pradesh, representing a combined investment of approximately $100 million and employing around 750 people. Its recently commissioned second facility has expanded manufacturing capabilities for vials, ophthalmic products, prefilled syringes, cartridges and oncology products, increasing annual production capacity to more than 200 million units.
Immacule currently serves more than 30 Indian and international pharmaceutical companies and supplies over 50 globally approved products. Viral Shah, founder of Acme and managing director of Immacule, will work with BDR Pharma to support the transition while focusing on Immacule’s expansion. o3 Capital served as the exclusive financial advisor to BDR Pharma on the transaction.
